Share Name Share Symbol Market Type Share ISIN Share Description
Fevertree Drinks Plc LSE:FEVR London Ordinary Share GB00BRJ9BJ26 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  24.00 1.97% 1,244.00 701,837 16:29:55
Bid Price Offer Price High Price Low Price Open Price
1,239.00 1,242.00 1,252.00 1,192.00 1,212.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Beverages 311.10 55.60 38.29 32.5 1,450
Last Trade Time Trade Type Trade Size Trade Price Currency
17:59:20 O 3,295 1,216.686 GBX

Fevertree Drinks (FEVR) Latest News (1)

More Fevertree Drinks News
Fevertree Drinks Investors    Fevertree Drinks Takeover Rumours

Fevertree Drinks (FEVR) Discussions and Chat

Fevertree Drinks Forums and Chat

Date Time Title Posts
01/7/202209:58FEVER TREE with chart8,247
28/1/202209:55Fevertree Drinks PLC (Fever-Tree)1,964
26/11/202111:18Fevertree - private investor971
26/3/201910:54Fevertree Drinks FY Results 26.03.19 Preview5

Add a New Thread

Fevertree Drinks (FEVR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Fevertree Drinks trades in real-time

Fevertree Drinks (FEVR) Top Chat Posts

Fevertree Drinks Daily Update: Fevertree Drinks Plc is listed in the Beverages sector of the London Stock Exchange with ticker FEVR. The last closing price for Fevertree Drinks was 1,220p.
Fevertree Drinks Plc has a 4 week average price of 1,192p and a 12 week average price of 1,192p.
The 1 year high share price is 2,871p while the 1 year low share price is currently 1,192p.
There are currently 116,550,000 shares in issue and the average daily traded volume is 733,947 shares. The market capitalisation of Fevertree Drinks Plc is £1,449,882,000.
porsche1945: Iv traded this and i think its a good trading share, I do the same with Ocado, the two have similarities tbh.
montyhedge: Totally agree, especially with one product companies.To me half this price about right.
philanderer: Bank of America raises Fevertree Drinks to 'neutral' (underperform) - price target 1,900 (2,150) pence Deutsche Bank cuts Fevertree Drinks price target to 3,350 (3,500) pence - 'buy' Barclays cuts Fevertree Drinks price target to 3,030 (3,200) pence - 'overweight' Goldman Sachs cuts Fevertree Drinks price target to 1,920 (2,100) pence - 'neutral' RBC cuts Fevertree Drinks price target to 1,600 (1,900) pence - 'sector perform'
edmondj: Lindsell Train reduces from 10.02% to 9.3% Https://
km18: Fevertree Drinks plc posted prelims for FY21 this morning. Fever-Tree delivered revenue growth of 23%, growing strongly across all markets and extending its position as a leading global premium mixer brand. Revenues were £311.1m, a new record, with adjusted EBITDA of £63m and diluted EPS of 38.19p. The business has been growing consistently strongly for the past decade and looks set to continue this pattern. FEVR has top notch profitability ratios and a strong balance sheet. Unsurprisingly investors have taken note of the success story, valuation remains stretched with forward PE ratio at 37.9 most expensive in the Beverages market. The business is impressive, but the share is excessively expensive. Monitor for now.... ...from WealthOracleAM
rmillaree: Never thought i woukld see the day where i am sat on the sidelines with no shares when you are buying Castelford T. I did well with my exit price ref these shares - not so well though with the result of where the cash was spent on other shares. If only i had parked sales proceeds as cash for now sigh.
philanderer: Lindsell Train star fund manager Nick Train has used cash from the buyout of Daily Mail and General Trust to top up his holdings in Fever-Tree (FEVR) and Experian (EXPN) after their shares slumped in the New Year growth selloff. The buy-and-hold manager of the Lindsell Train UK Equity fund and Finsbury Growth & Income (FGT) investment trust, who is under some pressure after falling behind the stock market and rivals in 2021, was left with a windfall of nearly £250m of cash after the Rothermere family took the Daily Mail publisher private in December. Train told investors he had ploughed the money across the two portfolios but had beefed up the stakes in tonic maker Fever-Tree and credit data provider Experian. ‘The falls in January have meant that we were able to take advantage and deploy this capital, perhaps more quickly and certainly on better terms than we expected. In particular, we were able to add to our holdings in Experian and Fever-Tree at notably lower prices as the month went on and they are now important positions,’ Train said in his monthly update.
wall street trader: A good downgrade always does wonders for a share price
toffeeman: Mixed feelings for posh tonic maker Fever-Tree Emma Powell Friday January 28 2022, 12.01am, The Times You’d think that investors would have learnt to be pessimistic when it comes to Fever-Tree’s earnings. Chasing market share has come at a price of heavy costs and margins that have shrunk over the past five years. And the prospect of any relief to all that has been hit by rapidly rising inflation. Higher transatlantic freight costs and raw materials prices mean that stronger sales won’t feed through to better earnings. The drinks group has guided towards earnings before interest, tax and other charges of between £69 million and £72 million for this year, below an analyst consensus forecast of £75 million. A margin that had been expected to return to growth is now set to be flat on last year at about 20 per cent. The maker of posh tonics has capitalised on the revival of gin in Britain and fancier tastes among drinkers willing to spend more on mixers. Rapid revenue growth had made the Aim-listed group a stock market darling, spurring a rise in the shares of more than 2,000 per cent between 2014 and a 2018 peak. But concerns over a slowdown in sales growth within a maturing UK market and the hefty costs associated with international expansion have hamstrung the shares since then. Pandemic impact aside, some of the challenges to margins have been one-offs, such as cash spent on cutting prices in the United States in 2020. But investment in adding customers — including hiring staff, marketing and taking on new premises — is a recurring drain on funds. Analysts at Liberum, who downgraded the stock from a “buy” to a “hold” on the back of yesterday’s trading update, cut their adjusted earnings forecasts for this year and next by 10 per cent, to £71.9 million and £89.7 million, respectively. The company reckons the margin will return to growth next year, which Liberum interprets as an adjusted pre-tax margin of 21.6 per cent. Bringing distribution closer to international markets should provide some relief against freight costs. A bottling facility on the east coast of America is due to step up production in the coming months; another is due to open in Australia next year. The premium tonic specialist argues that gaining market share is the main prize and it is willing to sacrifice margins to attain that, for now. Admittedly, revenue growth has been impressive, up almost a quarter last year and ahead of the level suggested in September. Revenue guidance for this year has been upgraded, too, encouraged by a recovery in higher-margin on-trade sales as pubs and bars reopen and expectation that at-home demand will stick above the pre-pandemic level. Heady sales expectations are built into the group’s enterprise value, which sits at almost eight times forecast sales for next year. That’s even after some froth coming out of the shares, which are down just over 40 per cent from their peak. But given the continued margin pressure, a share price that represents 51 times forward earnings, above an historic multiple of 45, is problematic. Efforts to maintain strong revenue growth could continue to have two negative side-effects. First, it means the drinks specialist will need to keep investing in staff, marketing and general product development as it seeks to broaden its range of mixers beyond its staple tonic and to expand further in America. Second, it limits the ability to push through price increases that would be substantial enough to ease pressure on margins, particularly given uncertainty over how long materials inflation and higher freight costs persist. You can understand that reluctance, to some extent, but it also means the shares are at risk of further punishment. Advice Avoid Why The current valuation leaves little room for error, which could materialise if inflation persists for longer than anticipated
martywidget: LON:FEVR - Fevertree Drinks Stock Price Target and Predictions: htTPS:// Fevertree Drinks (LON:FEVR)'s stock had its "neutral" rating restated by Citigroup in a report issued on Wednesday, Price reports. They presently have a GBX 2,300 ($31.03) price objective on the stock. Citigroup's target price would suggest a potential downside of 6.15% from the stock's previous close. Several other research firms have also issued reports on FEVR. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Fevertree Drinks in a research note on Wednesday, January 19th. Barclays increased their target price on Fevertree Drinks from GBX 2,400 ($32.38) to GBX 3,350 ($45.20) and gave the stock an "overweight" rating in a research note on Tuesday, December 14th. Deutsche Bank Aktiengesellschaft increased their target price on Fevertree Drinks from GBX 3,300 ($44.52) to GBX 3,560 ($48.03) and gave the stock a "buy" rating in a research note on Tuesday, January 18th. Finally, Berenberg Bank reiterated a "buy" rating and set a GBX 2,700 ($36.43) target price on shares of Fevertree Drinks in a research note on Wednesday, January 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of GBX 2,601.11 ($35.09).
Fevertree Drinks share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Fevertree ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220703 13:06:26